A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high-risk superficial bladder tumours undergoing intravesical therapy

BJU International

Volumn 104, Issue 3, 2009, Pages 336-339

  Whitson, Jared ^a   Berry, Anna ^b   Carroll, Peter ^a   Konety, Badrinath ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

BCG; Biological; Fluorescence; In situ hybridization; Neoplasm; Tumour markers; Urinary bladder

Indexed keywords

BCG VACCINE; INTERFERON; MITOMYCIN;

ADULT; AGED; ARTICLE; BLADDER TUMOR; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTOSCOPY; CYTOLOGY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HIGH RISK SUPERFICIAL BLADDER TUMOR; HUMAN; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR DIAGNOSIS; TUMOR GROWTH; TUMOR RECURRENCE;

ADMINISTRATION, INTRAVESICAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BCG VACCINE; EPIDEMIOLOGIC METHODS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INTERFERONS; MIDDLE AGED; MITOMYCIN; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; URINARY BLADDER NEOPLASMS;

EID: 68049112265     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08375.x     Document Type: Article

References (18)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2007. CA Cancer J Clin 2007 57 : 43 66
2. Lee R, Droller MJ. The natural history of bladder cancer. Implications for therapy. Urol Clin North Am 2000 27 : 1 13
3. Shelley MD, Kynaston H, Court J et al. A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int 2001 88 : 209 16
4. Sylvester RJ, van der Meijden AP, Oosterlinck W et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006 49 : 466 5
5. Meloni AM, Peier AM, Haddad FS et al. A new approach in the diagnosis and follow-up of bladder cancer. FISH analysis of urine, bladder washings, and tumors. Cancer Genet Cytogenet 1993 71 : 105 18
6. Sarosdy MF, Schellhammer P, Bokinsky G et al. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 2002 168 : 1950 4
7. Konety BR. Molecular markers in bladder cancer: a critical appraisal. Urol Oncol 2006 24 : 326 7
8. Pycha A, Mian C, Hofbauer J et al. Does topical instillation therapy influence chromosomal aberrations in superficial bladder cancer? J Urol 1998 159 : 265 9
9. Mengual L, Marin-Aguilera M, Ribal MJ et al. Clinical utility of fluorescent in situ hybridization for the surveillance of bladder cancer patients treated with bacillus Calmette-Guerin therapy. Eur Urol 2007 52 : 752 9
10. Kipp BR, Karnes RJ, Brankley SM et al. Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization. J Urol 2005 173 : 401 4
11. Smeets W, Pauwels R, Laarakkers L et al. Chromosomal analysis of bladder cancer. III. Nonrandom alterations. Cancer Genet Cytogenet 1987 29 : 29 41 (Pubitemid 17159853)
12. Mack D, Frick J. Diagnostic problems of urine cytology on initial follow-up after intravesical immunotherapy with Calmette-Guerin bacillus for superficial bladder cancer. Urol Int 1994 52 : 204 7
13. Libetta C, Rampino T, Dal Canton A. Polarization of T-helper lymphocytes toward the Th2 phenotype in uremic patients. Am J Kidney Dis 2001 38 : 286 95
14. Kwak B, Mulhaupt F, Myit S et al. Statins as a newly recognized type of immunomodulator. Nat Med 2000 6 : 1399 402
15. Bohle A, Brandau S. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol 2003 170 : 964 9
16. Hoffmann P, Roumeguere T, Schulman C et al. Use of statins and outcome of BCG treatment for bladder cancer. N Engl J Med 2006 355 : 2705 7
17. Kamat AM, Wu X. Statins and the effect of BCG on bladder cancer. N Engl J Med 2007 356 : 1276 7
18. Berglund RK, Savage CJ, Vora KC et al. An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder. J Urol 2008 180 : 1297 300